A market study, titled “Global Autoimmune Drugs Market 2016-2020,” has been featured on MarketResearchReports.biz’s online repository of market intelligence. This research report provides the answers to some of the pertinent questions in the realm of autoimmune disorder studies and their associated industries. In this report, various aspects of autoimmune disorders are examined that will mark trends and growth prospects in the global autoimmune drugs market in the future. Market size estimates and information about the changing competitive hierarchy is provided for the 2016-2020 period across the Americas, EMEA, and APAC regions.
The report states that autoimmune diseases affect almost 50 million Americans, as per the American Autoimmune Related Diseases Association (AARDA). In the event of an autoimmune disease, the body’s immune system, which protects the body against diseases, targets and destroys healthy tissues rather than destroying foreign bodies. This results in significant pain, inflammation, and sometimes even organ damage. Autoimmune diseases can interfere with normal functioning of the nervous system, musculoskeletal system, and cardiovascular system, or individual organs such as the skin, the kidneys, the lungs, and various glands and joints.
The report presents data about the top vendors in the global autoimmune drugs market, which are AbbVie Inc., Amgen Inc., F.Hoffmann-La Roche, Pfizer Inc., Biogen, and Johnson & Johnson Private Limited. Other prominent vendors in this market Eisai, AstraZeneca, Antares Pharma, Gilead Sciences, Daiichi Sankyo, Sandoz, AB Science, Morphotek, Lexicon Pharmaceuticals, Santarus, Vitae Pharmaceuticals, Immunomedics, Principia Biopharma, Celltrion, Boehringer Ingelheim, Astellas Pharma, Hospira, Coherus BioSciences, Alder BioPharmaceuticals, Can-Fite BioPharma, Novartis, KaloBios Pharmaceuticals, Novo Nordisk, Idera Pharmaceuticals, MedImmune, ChemoCentryx, Invion, Celgene, Sanofi, Merck, Ablynx, Opexa Therapeutics, Acorda Therapeutics, ImmuPharma, Regeneron Pharmaceuticals, Baxter, GSK, Incyte, Takeda Pharmaceuticals, and Eli Lilly.
According to the report, the global market for autoimmune drugs is largely driven by the large number of pipeline drugs for these diseases. This is because autoimmune diseases affect a considerably large population around the world, which requires an effective remedy for the conditions. However, due to loss of patent exclusivity of identified remedies, the market is witnessing hampered growth. Nevertheless, the increasing number of public awareness programs that apprise individuals about autoimmune disorders and their related therapies will be beneficial for this market.
The report on the autoimmune drugs market is formidable for its analysis of the various causes of autoimmune diseases and their associated clinical therapies. To present this, analysts reached out to research institutions and healthcare agencies for gathering relevant clinical data. Using an array of graphical representations, an analysis of the efficacy of autoimmune drugs in the past and how these drugs are expected to fare in clinical trials in the future are presented herein.
Other than this, the report discusses the competitive landscape of this market at length. Taking a cue from the past hierarchy of market participants, the report assesses their foothold in the market in light of changing trends and advancements in clinical studies.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org